



Grant of Options

February 17, 2021

Released : February 17, 2021 17:44

RNS Number : 4895P

MaxCyte, Inc.

17 February 2021

MaxCyte, Inc.
("MaxCyte" or the "Company")

Grant of Options

Gaithersburg, Maryland - 17 February 2021: MaxCyte (LSE: MXCT, MXCL, MXCN), the global clinical-stage cell-based therapies and life sciences company, announces that on 16 February 2021, a total of 729,200 options of common stock in the Company ("Common Stock") were granted to PDMRs who are directors or officers of the Company ("Option Grants"). Details of the Option Grants are given below:

Option Grants to PDMRs	
Doerfler, Doug	390,200
Holtz, Ron	177,600
Thompson, J. Stark	26,900
Mandell, Art	26,900
Erck, Stan	26,900
Brooke, Will	26,900
Johnston, John	26,900
Douglas, Richard	26,900
Total	729,200

In the case of the Executive Directors and other employees, Option Grants vest 12/48th of the total grant one year after date of grant, and thereafter vest 1/48th per month for 36 months after the date of grant. Option Grants for Non-Executive Directors fully vest at the end of twelve (12) months after date of grant. The Option Grants have an exercise price of £10.40 equal to the closing price of Maxcyte's stock on 16 February 2021.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Doerfler, Doug Holtz, Ron Thompson, J. Stark Mandell, Art Erck, Stan Brooke, Will Johnston, John Douglas, Richard
2	Reason for the notification	
a)	Position/status	Doerfler, Doug - CEO and Director Holtz, Ron - CFO and Director Thompson, J. Stark - Non-executive Chairman Mandell, Art - Non-executive Director Erck, Stan - Non-executive Director Brooke, Will - Non-executive Director Johnston, John - Non-executive Director Douglas, Richard - Non-executive Director
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Grant of Options over Shares of Common Stock

b)	Identification Code	US57777K1060
c)	Nature of the transaction	Exercise of options and Sale of Common Stock by PDMR
d)	Price(s) and volume(s)	<p>Doerfler, Doug - 390,200 at an exercise price of £10.40</p> <p>Holtz, Ron - 177,600 at an exercise price of £10.40</p> <p>Thompson, J. Stark - 26,900 at an exercise price of £10.40</p> <p>Mandell, Art - 26,900 at an exercise price of £10.40</p> <p>Erck, Stan - 26,900 at an exercise price of £10.40</p> <p>Brooke, Will - 26,900 at an exercise price of £10.40</p> <p>Johnston, John - 26,900 at an exercise price of £10.40</p> <p>Douglas, Richard - 26,900 at an exercise price of £10.40</p>
e)	Aggregated information	N/A
	- Aggregated volume	N/A
	- Price	N/A
f)	Date of the transaction	16 February 2021
g)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

About MaxCyte

MaxCyte is a world-leading provider of cell-engineering enabling technology and is responsible for helping to bring next-generation cell and gene-editing therapies to life. The Company's technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL, MXCN) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.

For further information, please contact:

MaxCyte Inc.

+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Accounting Officer

Nominated Adviser and Joint Corporate Broker

+44 (0)20 7886 2500

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

Rupert Dearden

Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith

+44 (0)20 7260 1000

Joint Corporate Broker
Stifel Nicolaus Europe Limited

+44 (0) 20 7710 7600

Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea

Corporate Broking

Nick Adams
Financial PR Adviser

Consilium Strategic Communications

+44 (0)203 709 5700

maxcyte@consilium-comms.com

Mary-Jane Elliott
Chris Welsh
Sukaina Virji

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHTRMRTMTBBBIB